Loading organizations...
Based in Schlieren, Switzerland, GlycoEra is a biotechnology company that develops novel biologics using its CustomGlycan glycoengineering platform to selectively degrade disease-causing proteins. The organization focuses on creating targeted treatments for severe autoimmune diseases, inflammatory disorders, and immuno-oncology indications. Operating with a workforce of 20 to 49 employees, the firm advances a pipeline of therapeutic candidates, including its lead program GE8820, which targets IgG4 autoantibodies for conditions like pemphigus and myasthenia gravis. To support its clinical proof-of-concept development under the leadership of Chief Executive Officer Ganesh V. Kaundinya, GlycoEra has raised 45 million Swiss francs ($49 million) in Series A funding from prominent life science investors, including Sofinnova Partners, 5AM Ventures, and Roche Venture Fund. The company was founded in 2020 as a spin-out from LimmaTech Biologics by Veronica Gambillara Fonck and Amir Faridmoayer.
GlycoEra has raised $179.0M across 2 funding rounds.
GlycoEra has raised $179.0M in total across 2 funding rounds.
GlycoEra has raised $179.0M across 2 funding rounds. Most recently, it raised $130.0M Series B in May 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2025 | $130M Series B | — | MAX Klement, BGV (biogeneration Ventures), Pfizer Venture Investments, Roche Venture Fund, Soffinova Partners, SR ONE, Westlake Village BioPartners | Announced |
| Nov 1, 2021 | $49M Series A | Soffinova Partners, Mira Chaurushiya, Monique Schiersing | MAX Klement, Pfizer Venture Investments, Roche Venture Fund, SR ONE, Westlake Village BioPartners, LimmaTech Biologics | Announced |
GlycoEra has raised $179.0M in total across 2 funding rounds.
GlycoEra's investors include Max Klement, BGV (BioGeneration Ventures), Pfizer Venture Investments, Roche Venture Fund, Soffinova Partners, SR One, Westlake Village BioPartners, Mira Chaurushiya, Monique Schiersing, LimmaTech Biologics.
GlycoEra AG is a biotechnology company developing precision biologics that selectively degrade disease-causing circulating proteins, primarily targeting autoantibodies in autoimmune diseases.[1][5] Its CustomGlycan platform engineers proteins with precise sugar structures (glycans) to leverage the body's natural degradation pathways, enabling rapid, deep removal of targets like pathogenic IgG4 without broad immunosuppression.[2][3][7] The lead candidate, GE8820, addresses IgG4-driven conditions such as pemphigus and primary membranous nephropathy, with clinical trials underway and a second program advancing.[4][5] GlycoEra serves patients with autoimmune and inflammatory diseases, solving the limitations of existing therapies that are nonspecific, have narrow therapeutic windows, and are relegated to late-stage use.[5][7] The company has shown strong growth, raising CHF 45 million ($49 million) in Series A (2021) and $130 million in Series B to fund clinical data and pipeline expansion.[3][4][6]
GlycoEra spun out from LimmaTech Biologics in January 2021, founded by a team of glycobiology and protein engineering experts, including co-founder Dominique Sirena, PhD (CMO).[3][4] The idea emerged from deep expertise in sugar engineering (glycoengineering), protein degradation, and biopharmaceutical development, aiming to harness natural glycan-mediated pathways for novel therapeutics.[1][2] Early traction came swiftly with a CHF 45 million Series A round in November 2021, led by investors like Sofinnova Partners and Bristol Myers Squibb.[3][6] Pivotal leadership additions followed: Ganesh V. Kaundinya, PhD, as President and CEO; Tanmoy Ganguly, PhD, as Chief Scientific Officer; and Georges Gemayel, PhD, as Board Chair.[3] Based in Wädenswil and Schlieren, Switzerland, with a U.S. site in Newton, Massachusetts, GlycoEra quickly advanced its pipeline toward clinical testing by late 2025.[1][4]
GlycoEra rides the wave of protein degradation therapeutics, expanding beyond intracellular PROTACs to extracellular targets—a frontier opened by glycan engineering amid surging interest in precision medicine.[4] Timing aligns with maturing autoimmune insights identifying specific autoantibodies as drivers, yet unmet by current blockers or immunosuppressants.[5][7] Market forces favor it: rising autoimmune prevalence, demand for early-line biologics with better safety, and biotech funding for degraders (evident in its $175M+ total raise).[3][4][6] GlycoEra influences the ecosystem by pioneering glycan-mediated biologics, potentially reshaping immunology pipelines and attracting partnerships like Bristol Myers Squibb.[3][6]
GlycoEra is poised to deliver first clinical data from GE8820 in 2026, validating its platform and expanding to additional autoimmune and beyond indications.[4][5] Trends like AI-driven protein design and combo therapies will amplify its degraders' reach, while regulatory nods for precision biologics could accelerate adoption. Its influence may grow through platform licensing or big pharma deals, evolving from pipeline builder to immunology leader—transforming targeted degradation from intracellular niche to extracellular powerhouse, much like its Series B momentum signals.[3][4][6]
